Fenofibrate plus ursodeoxycholic acid for PBC: a real-world study
Part of Digestive system clinical trials.
This trial is testing whether adding fenofibrate to the standard PBC medicine ursodeoxycholic acid helps people with primary biliary cholangitis. It's a real-world study, meaning it looks at how treatments work in everyday practice. You can join only if you have already completed an earlier fenofibrate study.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have already completed a previous study where you took fenofibrate for PBC (study number NCT05751967).
- If you are a woman who could get pregnant, you must use at least one barrier method (like condoms) plus another effective birth control method during the study and for 3 months after the last dose. Men with partners who could become pregnant must also follow these rules.
- You cannot have had to stop treatment with a drug called seladelpar in a previous PBC study because of side effects.
- You must not have any other medical condition that would make it unsafe or unfair for you to be in the trial, in the opinion of the study doctor.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests fenofibrate, a medicine that may help lower liver enzymes in people with primary biliary cholangitis (PBC). It looks at how well the drug works in everyday medical practice.
This study tests whether fenofibrate, a medicine that lowers fats in the blood, can help people with primary biliary cholangitis (a chronic liver disease) who haven't had treatment before. It aims to see if it is safe and effective as a first treatment option.
This trial tests adding prednisone (a steroid) to ursodeoxycholic acid (a bile acid medicine) for people with primary biliary cholangitis who have a specific type of liver inflammation. The goal is to see if the combination works better at controlling the disease than standard care.
This research study tracks how well Primary Biliary Cholangitis (PBC) responds to standard medication (UDCA) and what happens to patients' health over time. It may help doctors understand which treatments work best for different people.
This trial tests a drug called elafibranor for people with primary biliary cholangitis (PBC), a liver disease. It aims to see if the drug is safe and works well over a long time.
This trial tests whether the drug fenofibrate can help people with primary biliary cholangitis (PBC), a chronic liver disease. It is for patients who have already taken fenofibrate in a previous study and want to continue treatment.
Hear when a new Primary Biliary Cholangitis (PBC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.